Search tips
Search criteria 


Logo of molmedLink to Publisher's site
Mol Med. 2007 Jan-Feb; 13(1-2): 40–58.
PMCID: PMC1869619

Molecular Profile of Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis


Rheumatoid arthritis (RA) is a chronic inflammatory arthritis. Currently, diagnosis of RA may take several weeks, and factors used to predict a poor prognosis are not always reliable. Gene expression in RA may consist of a unique signature. Gene expression analysis has been applied to synovial tissue to define molecularly distinct forms of RA; however, expression analysis of tissue taken from a synovial joint is invasive and clinically impractical. Recent studies have demonstrated that unique gene expression changes can be identified in peripheral blood mononuclear cells (PBMCs) from patients with cancer, multiple sclerosis, and lupus. To identify RA disease-related genes, we performed a global gene expression analysis. RNA from PBMCs of 9 RA patients and 13 normal volunteers was analyzed on an oligonucleotide array. Compared with normal PBMCs, 330 transcripts were differentially expressed in RA. The differentially regulated genes belong to diverse functional classes and include genes involved in calcium binding, chaperones, cytokines, transcription, translation, signal transduction, extracellular matrix, integral to plasma membrane, integral to intracellular membrane, mitochondrial, ribosomal, structural, enzymes, and proteases. A k-nearest neighbor analysis identified 29 transcripts that were preferentially expressed in RA. Ten genes with increased expression in RA PBMCs compared with controls mapped to a RA susceptibility locus, 6p21.3. These results suggest that analysis of RA PBMCs at the molecular level may provide a set of candidate genes that could yield an easily accessible gene signature to aid in early diagnosis and treatment.


Rheumatoid arthritis (RA) is a chronic inflammatory disease causing synovial joint damage, disability, and a shortened life expectancy (1,2). An awareness of the destructive potential of RA has led to more aggressive use of disease-modifying anti-rheumatic drugs (DMARDs) (3) and the development of immune therapies targeted to molecules and cells important in the pathogenesis of RA. These include the TNF inhibitors infliximab, etanercept, and adalimumab (4). Synovial joint damage occurs early in the disease course, and many patients demonstrate erosions within a few months after becoming symptomatic (5). Recent evidence suggests that early aggressive therapy (infliximab and methotrexate) yields greater benefit than similar therapy after failure of other drugs (68). To initiate early aggressive therapy requires reliable and rapid determination of diagnosis and prognosis. In addition, factors used to predict a poor prognosis, including sex, age of onset, multiple joint involvement, rheumatoid factor, and the presence of the shared epitope of HLA-DR4, are not always reliable (912).

Gene expression profiling may allow early diagnosis, aid in identifying factors that predict poor prognosis, and help focus early, aggressive, and expensive therapy to those that would benefit the most. Expression analysis of tissues taken at the site of disease within a synovial joint is invasive and impractical on a routine basis. However, recent studies have demonstrated unique gene expression changes in peripheral blood mononuclear cells (PBMCs) from patients with cancer, multiple sclerosis, and lupus (1317). In this study, a genome-wide scan of PBMCs from normal volunteers and RA PBMCs was performed using oligonucleotide arrays representing 6800 human genes to explore gene expression in the PBMCs of individuals with RA.


Patient Selection

Patients with RA, defined by American College of Rheumatology (ACR) criteria (18), were identified in a rheumatology clinic with approval from the local research ethics committee. Demographic data including age, sex, and time since diagnosis were collected. A tender joint count (TJC 0-28), swollen joint count (JC 0-28), patient’s best global assessment (visual analog scale), and erythrocyte sedimentation rate (ESR) were performed to calculate a 28-joint disease activity score (DAS28). The presence of rheumatoid factor (RF) and the use of DMARDs were recorded. Blood was also collected from healthy volunteers with no previous diagnosis of RA or other chronic inflammatory diseases.

Isolation of RNA and Preparation of Labeled Hybridization Solutions

An 8-mL sample of venous blood was collected into CPT Vacutainer cell purification tubes (Becton Dickinson, Franklin Lakes, NJ, USA) and refrigerated immediately. Samples were immediately transferred to the laboratory, and PBMCs from the 9 RA and 13 normal volunteers were separated according to the manufacturer’s recommendations. Briefly, the tube was centrifuged at 1500g (2700 rpm) at room temperature, and PBMCs were isolated before being washed twice in PBS. Total RNA was extracted using the RNeasy minikit (Qiagen, Valencia, CA, USA). For each sample, 2 μg total RNA was used to generate cDNA as described (19). RNA quality was determined by observing distinct 28S and 18S ribosomal bands on an agarose gel. First-strand cDNA synthesis was performed under the following buffer conditions: 1× 1st-strand buffer (Invitrogen Life Technologies, Carlsbad, CA, USA), 10 mM DTT (Gibco/Invitrogen), 500 μM of each dNTP (Invitrogen Life Technologies), 400 units Superscript RT II (Invitrogen Life Technologies), and 40 units RNase inhibitor (Ambion, Austin, TX, USA). The reaction proceeded at 47°C for 1 h. Second-strand cDNA was synthesized with the addition of the following reagents at the final concentrations listed: 1× 2nd-strand buffer (Invitrogen Life Technologies), an additional 200 μM of each dNTP (Invitrogen Life Technologies), 40 units E. coli DNA polymerase I (Invitrogen Life Technologies), 2 units E. coli RNaseH (Invitrogen Life Technologies), and 10 units E. coli DNA ligase. The reaction proceeded at 15°C for 2 h; during the last 5 min of this reaction, 6 units T4 DNA polymerase (New England Biolabs, Beverly, MA, USA) was added. The resulting double-stranded cDNA was purified with the use of BioMag carboxyl-terminated particles as follows: 0.2 mg BioMag particles (Polysciences, Warrington, PA, USA) were equilibrated by washing three times with 0.5 M EDTA and resuspended at a concentration of 22.2 mg/mL in 0.5 M EDTA. The double-stranded cDNA reaction was diluted to a final concentration of 10% PEG/1.25 M NaCl, and the bead suspension was added to a final bead concentration of 0.614 mg/mL. The reaction was incubated at room temperature for 10 min. The cDNA/bead complexes were washed with 300 μL of 70% ethanol, the ethanol was removed, and the tubes were allowed to air dry. The cDNA was eluted with the addition of 20 μL of 10 mM Tris-acetate, pH 7.8, and incubated for 2 to 5 min, and the cDNA-containing supernatant was removed.

Purified double stranded cDNA (10 μL) was added to an in vitro transcription (IVT) solution which contained 1× IVT buffer (Ambion), 5000 units T7 RNA polymerase (Epicentre Technologies, Madison, WI, USA), 3mM GTP, 1.5 mM ATP, 1.2 mM CTP, and 1.2 mM UTP (Amersham/Pharmacia), 0.4 mM each bio-16 UTP and bio-11 CTP (Enzo Diagnostics, Farmingdale, NY, USA), and 80 units RNase inhibitor (Ambion). The reaction proceeded at 37°C for 16 h. Labeled RNA was purified with the use of an RNeasy kit (Qiagen). The RNA yield was quantified by measuring absorbance at 260 nm.

Hybridization to Affymetrix Microarrays and Detection of Fluorescence

Eleven in vitro synthesized transcripts from segments of bacterial genes were included in each hybridization reaction to generate a global standard curve to normalize the oligonucleotide microarrays to each other and estimate the sensitivity of the arrays (20). Purified biotinylated cRNA (10 μg) was hybridized to oligonucleotide arrays comprised of 6937 human gene qualifiers (human FL6800 array P/N900183, Affymetrix, Santa Clara, CA).

Raw fluorescent intensity values were collected and reduced with GeneChip v3.2 software (Affymetrix) as described (Affymetrix GeneChip Analysis Suite User Guide). This determined the probability of each gene qualifier represented on the array being absent, present, or marginal, as well as calculating a specific hybridization intensity value, or average difference, for each transcript. The relative abundances of the 11 bacterial control cRNA transcripts ranged from 1:300,000 (3 ppm) to 1:1000 (1000 ppm) stated in terms of the number of control transcripts per total transcripts. As determined by the signal response from these control transcripts, the sensitivity of detection of the arrays ranged between ~1:300,000 and 1:100,000 copies/million. The average difference for each transcript was normalized to frequency values as described (20).

Transcripts designated absent in all samples were excluded from the analysis; 3295 (49%) of the transcripts remained. Further analysis of the processed data was performed with GeneSpring version 7.1 (Agilent Technologies, Redwood City, CA, USA). To identify transcripts that were increased in the RA samples compared with controls, >50% (at least 5 of 9) of the samples had to be called present, with a frequency of 10 ppm or greater, and have a change in expression, relative to the average expression of the controls, of at least 2-fold. The resulting data set had 324 gene qualifiers. To find gene qualifiers whose expression was decreased, a list was generated of gene qualifiers from normal samples that were called present with a frequency of ≥ 10 ppm. The resulting list was filtered for an average decrease in expression, relative to the controls, of at least 2-fold in the disease samples. Six gene qualifiers met these criteria; 330 transcripts were used for the analyses. Annotation for each gene was determined based on GO, Entrez Gene, PubMed, and literature searches.

Statistical and Clustering Analyses

An unsupervised hierarchical clustering was performed on the 330 genes to group the samples on the basis of similarity of their expression profiles (21). Statistically significant differences in expression were determined using Welch ANOVA (22) coupled with two different multiple testing corrections. The Benjamini and Hochberg false discovery rate (FDR) (23) was applied with a P value <0.05, with 326 genes passing this criterion. The Bonferroni family-wise error rate (FWER) (24,25) was applied with a P value <0.05, with 189 gene qualifiers passing this criterion. Finally, a class prediction using the k-nearest neighbor method (26) was applied to the filtered data to determine which genes had the highest discrimination between normal and RA samples.


Characteristics of the RA patients used in the study, including demographics, disease activity scores, and DMARD use, are illustrated in Table 1. In total, 324 transcripts increased by at least two-fold between the RA and control subjects, and six transcripts decreased by at least twofold between the RA and control subjects (Table 2).

Table 1
Characteristics of RA patients including demographics, disease activity scores, and DMARD use.
Table 2
Differentially regulated transcripts.

Unsupervised Clustering

An unsupervised clustering analysis was performed on the 330 genes that passed the initial filtration, based on a hierarchical correlation coefficient algorithm (21). Samples were grouped based on similarity of expression. The resulting dendrogram describes the sample relationships by grouping the RA samples and controls by their expression patterns (Figure 1). Figure 1A depicts a region where expression levels in the RA samples were increased compared with the normal samples. This analysis suggests that there are significant differences in the gene expression of RA and control samples.

Figure 1
Unsupervised hierarchical cluster analysis of RNA from 9 RA and 13 control PBMC samples. Total RNA samples were analyzed on oligonucleotide arrays as described. In no case were samples pooled. Genes were selected for analysis if they had a present call, ...

ANOVA Analysis

To minimize the inclusion of genes not related to the disease state, several statistical approaches were used. The 330 transcripts that passed the initial filtration (Table 2) were subjected to a Student t test and a Welch ANOVA with two multiple testing corrections (22). To control for a proportion of genes that may appear in the analysis by chance, an FDR was calculated set to a threshold of 5%. This analysis defines a proportion of the genes that are expected to occur by chance relative to the total number of transcripts identified; 326 transcripts were called significant with this analysis (Table 2). In addition, the more stringent Bonferroni FWER using a P value cutoff of 0.05 was also performed, with 189 transcripts passing this analysis (Table 2).

Class Prediction

A k-nearest neighbor analysis was performed to identify a gene set that may distinguish the RA samples from normals. The prediction strength was evaluated using the 330 genes shown in Table 2. A list of predictor genes was assembled using the k-nearest neighbor method (26) to organize genes based on normalized expression levels. Cross-validation analyses comparing each sample to the model generated by the remaining samples were used to optimize the analysis parameters. This resulted in a number of neighbors value of 6 with a decision cutoff P value of 0.2 to predict expression patterns in RA vs. controls. Twenty-nine transcripts comprise the prediction gene set. The 29 prediction transcripts were grouped based on a hierarchical correlation to show the relationships (Figure 2).

Figure 2
Class prediction. Using a class prediction algorithm, a list of genes that most consistently distinguished diseased vs. normal samples was generated. Classification was generated by the k-nearest neighbors algorithm (26). The number of neighbors selected ...

Characterization of the RA Disease-Related Genes

The 330 differentially regulated transcripts were categorized into functional groups and are presented as the average fold change of RA frequency compared with that of the controls (Table 2). This analysis clustered the genes into 19 functional classes and highlighted one chromosomal location. Ten genes with increased expression in the RA PBMCs compared with normal controls map to an RA susceptibility locus, 6p21.3 (27) (Table 3). The functional classes are diverse and include genes involved in calcium binding, chaperones, cytokines, transcription, translation, signal transduction, extracellular matrix, integral to plasma membrane, integral to intracellular membrane, mitochondrial, ribosomal, structural, enzymes, and proteases. Many of these 330 genes or gene products are known to be differentially regulated in RA. Twenty-five genes were classified as unknown because they either coded for a hypothetical protein or were identified as an open reading frame of unknown function.

Table 3
Genes with increased expression in RA compared with normal PBMCs at the RA susceptibility locus 6p21.3

The k-nearest neighbor analysis identified genes that may be preferentially regulated in the RA samples. Of the 29 genes identified by the class prediction analysis (Figure 2B) to be expressed in the RA PBMCs compared with the controls, only RELA (NFκB p65) (28), IGF2 (insulin-like growth factor 2) (29)], FTH1 (ferritin heavy chain) (30), and SELP (selectin P) (31) have previously been associated with RA. Furthermore, both NF-κB and selectin P have been used as therapeutic targets in animal models (32,33). INPP5E (inositol polyphosphate-5-phosphatase E), STAB1 (stabilin), AGPAT1 (1-acylglycerol-3-phosphate O-acyltransferase 1), TCIRG1 (T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 protein A isoform 3), HD (Huntingtin), SREBF1 (sterol regulatory element binding factor 1), and IRF3 (interferon regulatory factor 3) are examples of genes that have not previously been associated with RA.


In this study, the mRNA levels of 6800 genes were measured in PBMCs from RA patients with active disease and normal individuals. All patients were on DMARD therapy that included methotrexate. Three hundred thirty differentially expressed transcripts were detected in at least 50% of the patients and exhibited a minimum of a two-fold change in expression from normal individuals. A number of genes previously thought to be involved in RA pathogenesis were detected in this study. These include the transcripts for TNF receptor TNFRSF1B (p75) and CCL5 (RANTES). TNFα has a key role in RA, and the expression of mRNA and protein of TNF receptors is increased in RA synovial membranes and sera (3436). In murine models, as well as TNFα transgenic and receptor knockout mice, the pathogenic activity of TNF has been well documented. Furthermore, both the soluble form of the TNF receptor and antibodies against TNF are efficacious in animal models and are effective therapies for RA (4,68,37,38). CCL5 is a chemokine expressed in the serum and synovial joints of patients with RA and is likely to play important roles in recruitment of inflammatory cells (39). A polyclonal antibody to RANTES improved symptoms in animals with adjuvant induced arthritis (40). RNA transcripts encoding proteins from a number of signaling pathways, including NF-κB, were present in increased amounts in individuals with RA, and many of these are targets for therapeutic blockade (41). NF-κB (RELA) has important roles in the production of inflammatory cytokines such as IL-1 and TNF (28). The presence of these known genes in the data set further validates the array data and analysis.

A k-nearest neighbor analysis was applied to the data set to identify genes preferentially expressed in the PBMCs from RA patients compared with controls. Twenty-nine genes were identified. Some of these genes have been previously identified as being differentially regulated in RA and include IGF2 (29), FTH1 (30), and SELP (31). SELP contributes to many inflammatory diseases and has been shown to mediate leukocyte interaction with endothelial cell wall (42). Levels of SELP are increased in the synovial fluid of RA patients (43). In the murine collagen-induced arthritis model, the deletion of SELP resulted in more severe disease compared with wild-type mice (44).

Many genes not previously known as being differently regulated in RA were also identified, for example, TCIRG1 (T-cell, immune regulator 1), INPP5E (inositol polyphosphate-5-phosphatase E), and STAB1 (stabilin). TCIRG1 is a seven-transmembrane, novel T cell protein that plays a role in T cell activation (45). Antibodies to TCIRG1 (TIRC7) prevent human T cell proliferation in vitro, inhibit type I subset–specific IFNγ and IL-2, but not the type II subset cytokine IL-4. A TIRC7 antibody prolonged survival in a rat model of acute kidney allograft rejection (45). TIRC7-null mice have disrupted T and B cell responses in vitro and in vivo, suggesting that TIRC7 may play a role in T and B lymphocyte balance (46).

INPP5E, a member of the inositol polyphosphate 5-phosphatase family, similar to INPP5D (Table 2), regulates PI-3 kinase signal transduction (47). AGPAT1 (1-acylglycerol-3-phosphate O-acyltransferase 1) catalyzes the conversion of lysophosphatidic acid (LPA) to phosphatidic acid (PA). LPA and PA are two phospholipids involved in signal transduction and phospholipid synthesis (48). Overexpression of AGPAT-1 in cell lines leads to the expression of both TNF-α and IL-6 in cells stimulated with IL-1β, suggesting that AGPAT-1 overexpression may amplify cellular signaling responses from cytokines (49).

Interestingly, 10 transcripts, including AGPAT1, differentially regulated in the RA PBMC from this study map to chromosome region 6p21.3, the major histocompatibility (MHC) locus III (27) (Table 3). Many of the genes in the MHCIII region have fundamental roles in a variety of cellular functions and include the inflammatory cytokines TNFα, LTA, LTB, and the advanced glycation end product receptor, RAGE (AGER) (27). Multifactor interactions contribute to the disease process at several levels. One hypothesis is that dys-regulation of genes in a locus could contribute to the etiology of the disease, perhaps through coordinated transcription of regions of a chromosome in response to stress or inflammation. RA is a complex autoimmune disorder, and expression analysis of a larger number of patients may validate this hypothesis.

STAB1 [also known as common lymphatic endothelial and vascular receptor (CLEVER-1 or FEEL-1)] was overexpressed in the RA PBMCs. This gene, identified by the k-nearest neighbor analysis, was expressed in 100% of RA PBMC samples and exhibited the highest fold change in this study (64-fold). Stabilin 1 is a large glycoprotein, multifunction scavenger receptor. Characterized as FEEL-1, this protein demonstrated a role as a scavenger receptor that binds to both advanced glycation end products as well as gram-positive and gram-negative bacteria (50,51). The receptor was shown to be expressed on mononuclear cells, tissue macrophages, and endothelial cells (5052). An antibody to FEEL-1 demonstrated a marked reduction in cell-to-cell interaction in a Matrigel tube formation assay, suggesting a role for the receptor in angiogenesis (50). CLEVER-1 has been demonstrated to be involved in the PMBC transmigration through vascular and lymphatic endothelium (52). The CLEVER-1 gene is encoded by 69 exons, and multiple isoforms are expressed in the endothelium (52). The potential function of CLEVER-1 in RA remains to be elucidated.

Several studies of gene expression in RA have been reported. Devauchelle et al. (53) focused on differences in expression in synovia isolated from RA patients compared with that of synovia from osteoarthritis patients. Watanabe et al. (54) reported on differences in expression between RA and normal synovial fibroblasts, and van der Pouw Kraan et al. (55) identified differences in gene expression in RA synovia, allowing the classification of different disease subtypes. A recent study by Bovin et al. (56), using a 12,000-gene oligonucleotide microarray, examined changes in gene expression between PBMCs from 14 RA patients vs. 7 sex-and age-matched controls, and they identified 25 genes that were discriminative. Although different filter criteria were applied to the data sets present here and the report from Bovin et al. (56), there were nine genes that overlapped between the two studies, including S100A12, NCF4, and GNG10. Of the genes that did not overlap, four were not present on the microarray used in this study, three showed changes but did not meet the strict data filtration criteria, and four were not called present in any of the samples. Another study by Olsen et al. (57), using a 4300-gene cDNA microarray, identified a gene expression signature for early-onset rheumatoid arthritis in PBMCs. In that study, the authors segregated the data based on those with longstanding and early-onset disease. There is some overlap between the Olsen et al. (57) study and the results presented here. Of the 44 genes identified, eight from Olsen, et al. also appeared in the present study. Of the 30 that do not, four were not on the human FL6800 array, 15 were not called present in any of the samples, and the others were not included due to the filtration criteria. In the results presented here, patients were selected from the high disease activity cohort, and during analysis, several filtration criteria were applied to the data set with several statistical analyses and a minimum expression criteria of at least 50% of the patients. These measures ensured that the resulting defined gene signature was as robust as possible.

It must be noted that RA patients possess a broad spectrum of disease severity and time of onset, and the comparisons above serve to highlight the multiple differences in patient selection criteria, study materials, protocols, and data analysis that exist in studies so far. Combining the data from our study with that of others, however, does point to several consistent changes in gene expression that would be useful to investigate further. For example, the increased expression of the RAGE ligand S100A12 has been observed in more than 1 study and, as a result, has highlighted the RAGE pathway as potentially important in RA; it is now subject to further study by our group.

The information from this study can be used in two major ways. First, it allows genes important in the pathogenesis of RA to be identified. These genes can then be investigated in detail to determine their potential roles in disease. Second, the power of DNA microarray profiling, with its ability to monitor the expression of multiple genes simultaneously, may allow the identification of patterns of gene expression associated with RA. This may enable rapid diagnosis of RA and predictions of prognosis, as well as response to, and side effects of, DMARDs. The use of these techniques is most advanced in oncology, where predictions of prognosis can be made for certain cancers (17). This provides clinically useful information that guides decisions about how aggressive a treatment regimen should be for a given patient. There is a marked difference in the clinical features of RA between individuals, and molecular phenotyping (or patient profiling) may identify or characterize different disease subgroups and courses of disease progression.

A weakness of global gene expression analysis techniques lies in identifying the relationship of changes in gene expression to the disease process. Changes in gene expression may either cause a disease process or occur as a consequence of it. The presence of gene expression changes in genes that have been associated with RA validates the data set. However, not all genes are primarily regulated by changes in mRNA levels, with many being subject to posttranscriptional regulation. TNF, the best-validated molecular therapeutic target in RA, does not emerge from this type of analysis. This study examined expression in nine RA patients and identified a set of genes that is preferentially expressed in RA patients compared with controls. Although the data are intriguing, samples from a larger number of patients would aid in a class prediction to determine which genes are most associated with disease state and type of prognosis. It is interesting to note that a recent study of PBMC expression profiles in several autoimmune diseases showed that, whereas all diseases displayed profiles that differed from a normal immune response, not all diseases could be clearly distinguished from each other (58).

Gene expression studies on PBMCs may not exactly represent the situation within the inflamed synovial membranes of RA. RA is a systemic disease, however, and differences in cytokine production and phenotype of PBMCs in RA have been demonstrated (5961). This approach has the advantage of being a rapid and minimally invasive way of obtaining cells from patients. The usefulness of assaying tissue samples in RA is limited by availability and sampling bias due to regional differences in disease activity in synovia. However, if the diagnostic/predictive results of a gene expression profile can be demonstrated, PBMCs are a readily accessible source of cells.

The use of oligonucleotide microarrays enables a broader view of complex inflammatory diseases, such as RA. The simultaneous measurement of multiple mRNA transcripts allows an increased understanding of the complexity of proteins that may be interacting in a disease state rather than focusing on one or two at a time. This study identified 330 mRNA transcripts that were differentially regulated in the PBMCs from RA patients compared with normal volunteers. Having demonstrated that these techniques can be used with PBMCs, the next step involves looking at patterns of gene expression in individuals over time and detailed phenotypic examination of these individuals to determine patterns of gene expression associated with different features of RA.


The authors thank Dr. James C. Keith, Jr., for reviewing the manuscript.


Online address:


1. Markenson JA. Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Semin Arthritis Rheum. 1991;21(2 Suppl 1):4–12. [PubMed]
2. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum. 2001;44(12):2746–9. [PubMed]
3. Guidelines for the management of rheumatoid arthritis: update. Arthritis Rheum. 2002;46:328–46. No author. [PubMed]
4. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9:1245–50. [PubMed]
5. van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp’s method (van der Heijde modification) J Rheumatol. 1995;22:1792–6. [PubMed]
6. Bathon JM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93. [PubMed]
7. Lipsky PE, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602. [PubMed]
8. Quinn MA, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelvemonth randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27–35. [PubMed]
9. Combe B, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum. 2001;44:1736–43. [PubMed]
10. Dixey J, Solymossy C, Young A. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS) J Rheumatol. 2004;69 (Suppl):48–54.
11. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64:196–201. [PMC free article] [PubMed]
12. van Zeben D, Breedveld FC. Prognostic factors in rheumatoid arthritis. J Rheumatol. 1996;44(Suppl):31–3.
13. Aune TM, Maas K, Parker J, Moore JH, Olsen NJ. Profiles of gene expression in human autoimmune disease. Cell Biochem Biophys. 2004;40:81–96. [PubMed]
14. Mandel M, Gurevich M, Pauzner R, Kaminski N, Achiron A. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol. 2004;138:164–70. [PubMed]
15. Qing X, Putterman C. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2004;3:505–9. [PubMed]
16. Rus V, et al. Gene expression profiling in peripheral blood mononuclear cells from lupus patients with active and inactive disease. Clin Immunol. 2004;112:231–4. [PubMed]
17. van’t Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6. [PubMed]
18. Arnett FC, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24. [PubMed]
19. Clancy BM, et al. A gene expression profile for endochondral bone formation: oligonucleotide microarrays establish novel connections between known genes and BMP-2-induced bone formation in mouse quadriceps. Bone. 2003;33:46–s63. [PubMed]
20. Hill AA, Brown EL, Whitley MZ, Tucker-Kellogg G, Hunter CP, Slonim DK. Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls. Genome Biol. 2001;2:RESEARCH0055. [PMC free article] [PubMed]
21. Chiang DY, Brown PO, Eisen MB. Visualizing associations between genome sequences and gene expression data using genome-mean expression profiles. Bioinformatics. 2001;17(Suppl 1):S49–55. [PubMed]
22. Welch BL. On the comparison of several mean values: an alternative approach. Biometrika. 1951;38:330–6.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B. 1995;57:289–300.
24. Bonferroni CE. (1935) Il calcolo delle assicurazioni su gruppi di teste. Studi in onore del Professore Salvatore. Rome. p. 11–60.
25. Bonferroni CE. Teoria statistica delle classi e calcolo delle probabilita. Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di Firenze. 1936;8:3–62.
26. Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–7. [PubMed]
27. Jawaheer D, et al. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum. 2003;48:906–16. [PubMed]
28. Foxwell BM, Bondeson J, Brennan F, Feldmann M. Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogeneity in the requirement for NFkappaB in tumor necrosis factor production. Ann Rheum Dis. 2000;59(Suppl 1):i54–59. [PMC free article] [PubMed]
29. Keyszer GM, et al. Detection of insulin-like growth factor I and II in synovial tissue specimens of patients with rheumatoid arthritis and osteoarthritis by in situ hybridization. J Rheumatol. 1995;22:275–81. [PubMed]
30. Ota T, Katsuki I. Ferritin subunits in sera and synovial fluids from patients with rheumatoid arthritis. J Rheumatol. 1998;25:2315–8. [PubMed]
31. Akin E, Aversa J, Steere AC. Expression of adhesion molecules in synovia of patients with treatment-resistant lyme arthritis. Infect Immun. 2001;69:1774–80. [PMC free article] [PubMed]
32. Makarov SS. NF-kappaB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res. 2001;3:200–6. [PMC free article] [PubMed]
33. Sumariwalla PF, Malfait AM, Feldmann M. P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumor necrosis factor. Clin Exp Immunol. 2004;136:67–75. [PubMed]
34. Brennan FM, Gibbons DL, Mitchell T, Cope AP, Maini RN, Feldmann M. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol. 1992;22:1907–12. [PubMed]
35. Brennan FM, Gibbons DL, Cope AP, Katsikis P, Maini RN, Feldmann M. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action. Scand J Immunol. 1995;42:158–65. [PubMed]
36. Cope AP, et al. Differential regulation of tumor necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. Cytokine. 1993;5:205–12. [PubMed]
37. Shealy DJ, et al. Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res. 2002;4:R7. [PMC free article] [PubMed]
38. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 1992;89:9784–8. [PubMed]
39. Boiardi L, Macchioni P, Meliconi R, Pulsatelli L, Facchini A, Salvarani C. Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin Exp Rheumatol. 1999;17:419–25. [PubMed]
40. Barnes DA, et al. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest. 1998;101:2910–9. [PMC free article] [PubMed]
41. Firestein GS. NF-kappaB: Holy Grail for rheumatoid arthritis? Arthritis Rheum. 2004;50:2381–6. [PubMed]
42. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J. 1995;9:866–73. [PubMed]
43. Hosaka S, Shah MR, Pope RM, Koch AE. Soluble forms of P-selectin and intercellular adhesion molecule-3 in synovial fluids. Clin Immunol Immunopathol. 1996;78:276–82. [PubMed]
44. Bullard DC, et al. Acceleration and increased severity of collagen-induced arthritis in P-selectin mutant mice. J Immunol. 1999;163:2844–9. [PubMed]
45. Utku N, et al. Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity. 1998;9:509–18. [PubMed]
46. Utku N, Boerner A, Tomschegg A, Bennai-Sanfourche F, Bulwin GC, Heinemann T, Loehler J, Blumberg RS, Volk HD. TIRC7 deficiency causes in vitro and in vivo augmentation of T and B cell activation and cytokine response. J Immunol. 2004;15:2342–52. [PubMed]
47. Tomlinson MG, Heath VL, Turck CW, Watson SP, Weiss A. SHIP family inositol phosphatases interact with and negatively regulate the Tec tyrosine kinase. J Biol Chem. 2004;279:55089–96. [PubMed]
48. Aguado B, Campbell RD. Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the class III region of the human major histocompatibility complex. J Biol Chem. 1998;273:4096–105. [PubMed]
49. West J, et al. Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signaling responses in cells. DNA Cell Biol. 1997;16:691–701. [PubMed]
50. Adachi H, Tsujimoto M. FEEL-1, a novel scavenger receptor with in vitro bacteria-binding and angiogenesis-modulating activities. J Biol Chem. 2002;277:34264–70. [PubMed]
51. Tamura Y, et al. FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem. 2003;278:12613–7. [PubMed]
52. Salmi M, Koskinen K, Henttinen T, Elima K, Jalkanen S. CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium. Blood. 2004;104:3849–57. [PubMed]
53. Devauchelle V, et al. DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. Genes Immun. 2004;5:597–608. [PubMed]
54. Watanabe N, et al. Gene expression profile analysis of rheumatoid synovial fibroblast cultures revealing the overexpression of genes responsible for tumor-like growth of rheumatoid synovium. Biochem Biophys Res Commun. 2002;294:1121–9. [PubMed]
55. van der Pouw Kraan TC, van Gaalen FA, Huizinga TW, Pieterman E, Breedveld FC, Verweij CL. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun. 2003;4:187–96. [PubMed]
56. Bovin LF, et al. Blood cell gene expression profiling in rheumatoid arthritis: discriminative genes and effect of rheumatoid factor. Immunol Lett. 2004;93:217–26. [PubMed]
57. Olsen N, et al. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis. 2004;63:1387–92. [PMC free article] [PubMed]
58. Maas K, et al. Cutting edge: molecular portrait of human autoimmune disease. J Immunol. 2002;169:5–9. [PubMed]
59. Hirano T, et al. Comparative study of lymphocyte-suppressive potency between prednisolone and methylprednisolone in rheumatoid arthritis. Immunopharmacology. 2000;49:411–7. [PubMed]
60. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS. Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1) Clin Exp Immunol. 1996;106:190–6. [PubMed]
61. Schulze-Koops H, Davis LS, Kavanaugh AF, Lipsky PE. Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation. Arthritis Rheum. 1997;40:639–47. [PubMed]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ